1. Home
  2. INSM vs CAG Comparison

INSM vs CAG Comparison

Compare INSM & CAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • CAG
  • Stock Information
  • Founded
  • INSM 1988
  • CAG 1919
  • Country
  • INSM United States
  • CAG United States
  • Employees
  • INSM N/A
  • CAG N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • CAG Packaged Foods
  • Sector
  • INSM Health Care
  • CAG Consumer Staples
  • Exchange
  • INSM Nasdaq
  • CAG Nasdaq
  • Market Cap
  • INSM 12.5B
  • CAG 14.1B
  • IPO Year
  • INSM 2000
  • CAG N/A
  • Fundamental
  • Price
  • INSM $72.27
  • CAG $29.52
  • Analyst Decision
  • INSM Strong Buy
  • CAG Hold
  • Analyst Count
  • INSM 16
  • CAG 10
  • Target Price
  • INSM $82.00
  • CAG $31.00
  • AVG Volume (30 Days)
  • INSM 1.8M
  • CAG 5.9M
  • Earning Date
  • INSM 10-24-2024
  • CAG 10-02-2024
  • Dividend Yield
  • INSM N/A
  • CAG 4.74%
  • EPS Growth
  • INSM N/A
  • CAG N/A
  • EPS
  • INSM N/A
  • CAG 1.02
  • Revenue
  • INSM $328,605,000.00
  • CAG $11,941,800,000.00
  • Revenue This Year
  • INSM $19.10
  • CAG $0.25
  • Revenue Next Year
  • INSM $44.67
  • CAG $1.35
  • P/E Ratio
  • INSM N/A
  • CAG $28.93
  • Revenue Growth
  • INSM 21.94
  • CAG N/A
  • 52 Week Low
  • INSM $21.92
  • CAG $25.16
  • 52 Week High
  • INSM $80.53
  • CAG $33.24
  • Technical
  • Relative Strength Index (RSI)
  • INSM 46.30
  • CAG 30.58
  • Support Level
  • INSM $71.11
  • CAG $32.22
  • Resistance Level
  • INSM $73.81
  • CAG $32.90
  • Average True Range (ATR)
  • INSM 2.15
  • CAG 0.53
  • MACD
  • INSM -0.10
  • CAG -0.41
  • Stochastic Oscillator
  • INSM 36.26
  • CAG 9.73

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

About CAG ConAgra Brands Inc.

Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of fiscal 2024 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the us retail channel, with just 9% of fiscal 2024 revenue coming from international markets and 10% from foodservice.

Share on Social Networks: